Background. The degree of cardiac hypertrophy is not only load dependent: Among other factors, the renin-angiotensin system may play a role in the regulation of cardiac myocyte growth.
For several years, humoral mechanisms such as the renin-angiotensin system and the sympathetic nervous system have been postulated to play a role in the regulation of cardiac cell growth.1-4 However, the exact role of these neurohumoral systems in the development of cardiac hypertrophy in response to increased mechanical load still remains to be eluci-dated. The renin-angiotensin system may be a serious candidate in mediating or potentiating cardiac growth for several reasons. Cardiac angiotensin II receptors have been demonstrated in membrane preparations from neonatal and adult normal and hypertrophic rat myocardium.5,6 Angiotensin II is a potent, direct stimulus of protein synthesis and growth in cultured cardiomyocytes.1 Genetic messages for renin and angiotensinogen have been demonstrated in the rat heart.2,7-9 The presence of angiotensin converting enzyme (ACE) activity in the heart has also been ascertained by direct in vitro determinations8 and by quantitative autoradiography.10 Several lines of evidence suggest that the cardiac renin-angiotensin system may play a role in some models of pressure overload-induced cardiac hypertrophy in rats. Angiotensinogen mRNA increases in left ventricles exposed to pressure overload induced by abdominal aortic banding.7 Angiotensin converting en-zyme inhibitors (ACEI) cause the regression of already established cardiac hypertrophy induced by ascending aortic or abdominal aortic constriction despite persistent increased afterload.11-'3 Moreover, ACEI can prevent the development of cardiac hypertrophy in animal models of pressure overload induced by constriction of the abdominal aorta above the renal arteries.7,13 However, ACEI did not prevent the development of cardiac hypertrophy when the constriction was placed on the ascending aorta,11,12'4 suggesting that growth-promoting mechanisms may differ from one to another model of pressure overload-induced left ventricular (LV) hypertrophy.
To what extent the renin-angiotensin system plays a role in the development of volume overload-induced cardiac hypertrophy has so far been assessed in only one study. 15 Chronic captopril treatment started 24 hours after inducing aortic insufficiency in rats reduced the development of LV dilation and hypertrophy. This improvement was associated with beneficial changes in central hemodynamics. Changes in either plasma or cardiac renin activity were not reported.
A highly reproducible model of volume overload in rats can be induced by an abdominal aortocaval shunt. 16 This model was used in the present study for the assessment of 1) changes in hemodynamics and in plasma and cardiac renin activity during the development of cardiac hypertrophy in response to two levels of volume overload and 2) the effects of chronic blockade of the renin-angiotensin system by the ACEI enalapril or the nonpeptide angiotensin II receptor blocker losartan (DuP 753) started before shunt surgery on changes in cardiac anatomy and hemodynamics. The reninangiotensin system was blocked at two different levels since despite effective blockade of angiotensin converting enzyme by ACEI, generation of angiotensin II in the heart may still be possible by an angiotensin II-forming enzyme resistant to ACEI.17 Indeed, despite similar effects of the two drugs on cardiac and peripheral hemodynamics, only losartan significantly prevented right ventricular (RV) and LV hypertrophic responses to an increase in cardiac volume load by an aortocaval shunt.
Methods

Animals
Male Wistar rats weighing 200-225 g were obtained from Charles River Breeding Laboratories (Montreal, Canada). Rats were housed two per cage, given food and water ad libitum, and kept on a 12-hour light-dark cycle. After an acclimatization period of at least 3 days, they were randomized into three groups (control, small shunt, big shunt) for experimental protocol I and into two groups (control and big shunt) for experimental protocols II and III. Animals were weighed on the day of surgery, weekly thereafter, and on the day of hemodynamic assessments.
Aortocaval Shunt
Under halothane-nitrous oxide-oxygen anesthesia, shunt surgery was performed using the technique described by Garcia and Diebold. 16 Two different sizes of shunt (i.e., big and small) were produced by using an 18- therford, N.J.). Sham-operated animals serving as controls were subjected to the same surgical procedure as described above with the exception of puncturing the aorta and the inferior vena cava.
Experimental Protocol I: Aortocaval Shunt and Changes in Cardiac Hemodynamics, Cardiac Anatomy, and Renin Activity
To assess the time course of changes to acute, shortterm, and chronic cardiac volume overload, hemodynamic parameters, cardiac anatomy, and renin activity were evaluated at 1, 7, 28, and 49 days after induction of the aortocaval shunt using different groups of rats at each time point.
Cardiac hemodynamics. On the day of study, rats were anesthetized with halothane-nitrous oxide-oxygen, and a PE-50 catheter (Clay Adams, Parsippany, N.J.) filled with heparinized saline (100 IU/mL) was inserted into the LV via the right common carotid artery and into the right atrium via the right external jugular vein. Catheters were exteriorized on the neck of the animal. After a 4-hour recovery period from anesthesia, LV end-diastolic pressure (LVEDP), LV peak systolic pressure (LVPSP), and right atrial pressure (RAP) were assessed as described by Fields et al. 18 Heart rate (HR) was calculated from the curve of LVPSP and LVEDP recorded at a paper speed of 10 mm/sec. Resting hemodynamics were assessed in conscious, unrestrained rats after a 30-minute acclimatization period. The arterial cannulae were then removed from the transducer, and a blood sample (600 ,L) was collected into a chilled microcentrifuge tube containing 0.0026 M EDTA for determination of plasma renin activity (PRA). The same amount of 0.9% saline was injected to replace the lost blood volume.
Cardiac anatomy. At the end of an experiment under pentobarbital anesthesia, the chest cavity was opened, the heart was arrested in diastole by intravenous injection of 1 M KCl, rapidly excised, and placed into ice-cold saline to remain in diastole and to remove the blood. After removal of the atria and great vessels, the ventricles were blotted dry, and the RV was dissected along its septal insertion from the rest of the ventricular mass. The mass of the LV was divided by two transverse cuts at one-third and two-thirds the length, and the mass of the RV was divided into two approximately equal parts. The basal part of the LV and its apex as well as one part of the RV were washed in 0.1 M ice-cold sodium phosphate, pH 6.0, until all visible blood was removed. The samples were then blotted dry and placed separately in labeled aluminum foil in dry ice. These samples were stored at -70°C for subsequent assessment of tissue renin activity. The middle slice of the LV was used for assessment of the LV wall thickness and internal diameters as previously described by Tsoporis et al. 19 Dry LV and RV weights were determined after drying the middle slice of the LV and one part of the RV in an oven at 37°C for 72 hours.
Renin activity. Renin activity in plasma was determined by an antibody-trapping technique as described by Poulsen and Jorgensen.20 The detection limit was 100 pg of angiotensin I formed during the incubation period. The day-to-day variation of assay was +5% (SD). Cardiac tissue samples for assessment of renin activity were prepared by the technique described by Dzau and or 20- 
Effects of Induction of the Aortocaval Shunt
Hemodynamic changes. LVEDP was significantly elevated in rats with either a small or big aortocaval shunt at 1 day after surgery and was significantly higher in rats with a big shunt than in rats with a small one. Subsequently, LVEDP decreased but remained significantly increased in both shunt sizes up to 49 days after surgery (Table 1 ). In contrast, RAP showed no significant changes (Table 1) . Rats with a big aortocaval shunt had a significantly lower LVPSP at all time points of the follow-up compared with controls. LVPSP of rats with a small aortocaval shunt was between the normal values and values of rats with a big shunt ( Table 1) . Systolic and diastolic blood pressure corresponded with changes in LVPSP, i.e., were significantly lower in rats with a big shunt compared with controls at both time points of follow-up (Table 2) .
HR was not significantly changed by either shunt size (Table 3 ). CI was increased by 20% and 40% in animals with a big aortocaval shunt because of an increase in stroke volume at 7 and 28 days after surgery (Table 3) . TPRI (inclusive shunt) was significantly decreased in animals with an aortocaval shunt ( Table 3) .
Plasma and tissue renin activity. PRA was significantly increased at 1 day after surgery in both shunt groups. Thereafter, PRA decreased to normal in rats with a small shunt within 28 days but remained significantly elevated in rats with a big shunt up to 49 days after surgery ( Figure 1 ). Cardiac tissue renin activity followed a similar time course of changes as PRA in rats with either a small or big shunt. Renin activity in both the right and left ventricles was significantly increased at 1 day after surgery in rats with a small or big fistula and returned to normal values in both ventricles after 28 days, with the exception of renin activity in the right ventricle that remained elevated in rats with a big shunt (Figure 2) . Cardiac anatomy. LV weight increased by 24%, 40%, and 59% at 7, 28, and 49 days after surgery in rats with a big aortocaval shunt (Figure 3) . A small shunt increased LV weight by 14%, 17%, and 25% at these time points (Figure 3 ). The small and big aortocaval shunts increased RV weight 30% and 76% at 28 days after surgery with no further increase at 49 days ( Figure 3) .
A big aortocaval shunt increased the LV (major) internal diameter by 14%, 20%, and 26% at 7, 28, and 49 days after surgery, with only a small effect (+3%, +3%, and +6%) on LV wall thickness at these same time points (Figure 4) . A small shunt increased the LV (major) internal diameter by 8% and 10% at 28 and 49 days after surgery and wall thickness only by 2% and 4% (Figure 4 ). The wall thickness/radius ratio decreased significantly in rats with either the small or big shunt compared with controls ( Figure 4 ). There were no differences in percent dry weight of LV and RV between the groups at any time point (data not shown (Table 2 ). The lower pressures in rats with the aortocaval shunt were not consistently further lowered by either losartan or enalapril (Table 2) . No obvious differences in hemodynamic responses to either drug treatment were observed.
Neither enalapril nor losartan significantly changed the CI in control or shunt animals at both time points of follow-up (Table 3) ; small increases in HR and small decreases in SVI maintained CI at levels close to those in untreated shunt groups (Table 3 ). Enalapril and losartan significantly decreased TPRI only in treated controls at 28 days after surgery (Table 3) . Plasma and tissue renin activity. Chronic enalapril treatment increased PRA and renin activity in the LV at both 7 and 28 days after surgery. Losartan did not affect plasma or cardiac renin activity (Table 5) .
Cardiac anatomy. Enalapril treatment started before surgery did not prevent the increases in LV ( Figure 5 ) and RV weight ( Figure 6 ) at 7 and 28 days after surgery. Changes in wall thickness and LV internal diameter were not affected by enalapril at 7 days after induction of the shunt. However, enalapril partly reduced LV dilation induced by an aortocaval shunt at 28 days compared with untreated shunt rats (Table 6 ).
In contrast, losartan significantly attenuated the development of LV hypertrophy by 50% and 30% at 7 and 28 days after induction of an aortocaval shunt ( Figure  5 ). The hypertrophy of the RV was reduced in losartantreated rats by 20% and 50% at 7 and 28 days after induction of the shunt (Figure 6 ). Losartan prevented the increases in wall thickness and dilation of the LV accompanying the hypertrophic response to cardiac volume overload at 7 days after surgery and significantly attenuated both these structural changes of the LV at 28 days after shunt induction (Table 6) .
Body weight. The aortocaval shunt with or without concomitant treatment did not affect significantly the body weight (at 28 days: enalapril experiment: control, 422+13 g; shunt, 413+8 g; control+enalapril, 415+8 g; shunt+enalapril, 405+± 15 g; no significant differences; losartan experiment: control, 378± 14 g; shunt, 382±9 g; control+losartan, 388±9 g; shunt+losartan, 368+13 g; no significant differences). Changes in Plasma and Cardiac Renin Activity by an Aortocaval Shunt
The peak of PRA was found shortly after induction of the shunt, and whereas PRA decreased to control levels within weeks after a small shunt, it remained increased in rats with a big shunt up to 49 days. This is in concert with the results of previous studies in dogs and rats that showed an initial stimulation of neurohumoral systems, i.e., sympathetic nervous system and renin-angiotensinaldosterone system, after opening an aortocaval shunt.29'34-36 This response appears to be a function of the size of the aortocaval shunt and consequently the inability of the heart to keep the blood pressure within the normal range.34-36 Once a new steady state has developed, PRA, aldosterone secretion, and plasma catecholamines return toward normal.29'36'37 Angiotensin II-mediated arteriolar vasoconstriction maintains the arterial blood pressure in the early stages after induction of an aortocaval shunt in dogs31'34 and rats (Ruzicka and Leenen, unpublished observations). Although the total peripheral resistance is reduced in shunt animals, resistance is increased in certain vascular beds as a result of high levels of angiotensin II.29, 31, 34 Thus, total peripheral resistance is prevented from falling to excessively low levels. Moreover, an increased generation of angiotensin II contributes through increases in renal sodium and fluid reabsorption to increased blood volume, which in the long term contributes to the increase in cardiac output.29 Cardiac renin activity followed the changes of PRA, i.e., peaks in the right and left ventricles were measured shortly after surgery, and cardiac renin activity was higher with a big shunt than with a small one. Since an aortocaval shunt decreases LV renin mRNA levels and after bilateral nephrectomy an aortocaval shunt no longer increases LV renin activity (Ruzicka et al, unpublished observation), it appears that during the development of volume overload-induced cardiac hypertrophy, there is minimal or no increased contribution of heart-originated renin activity. Hearts are exposed to increased plasma renin activity, which, because of up- shunt.31,34,36 Overall, there were no major differences in the effects of the two treatments on hemodynamics, similar to that reported in a rat model of heart failure by myocardial infarction. 22 Despite the fact that both drugs had similar effects on cardiac and peripheral hemodynamics, major differences were found regarding anatomic changes of the heart in response to cardiac volume overload. Treatment with the ACEI enalapril did not prevent the hypertrophic response of the heart to volume overload but did cause a modest decrease in LV internal diameter after 28 days of treatment. More prolonged treatment may have caused more clear effects, as noted by Gay'5 for the effects of captopril treatment for 2 months on aortic insufficiency-induced cardiac changes. In contrast, the angiotensin II receptor blocker losartan significantly attenuated the hypertrophic response of both LV and RV to cardiac volume overload. The LV dilation was prevented by losartan at 7 days and significantly attenuated at 28 days after shunt surgery.
Because the two drugs showed similar beneficial hemodynamic effects but contrasting results regarding the hypertrophy of both RV and LV and remodeling of LV in response to cardiac volume overload, it appears that enalapril treatment may not have blocked or even activated a trophic mechanism. In the heart, angiotensin II can be generated from angiotensin I either by ACE increased plasma and LV renin activity. In the presence of an angiotensin II-forming enzyme resistant to ACEI,17 increased amounts of angiotensin II may have been generated. In contrast, in the dose used, losartan22 (a competitive angiotensin II receptor antagonist) and its active metabolite EXP 3174 (a noncompetitive angiotensin II receptor antagonist), which contributes to its overall effect in rats,40 rules out a contribution of angiotensin II in the hypertrophic response of the heart to cardiac volume overload. The differences observed in the effects of enalapril and losartan on cardiac hypertrophy despite similar effects on cardiac and peripheral hemodynamics may therefore reflect differences in "effective" inhibition of the trophic effects of angiotensin II on the heart. Alternatively, enalapril in the dose used may have caused ineffective blockade of ACE and angiotensin II formation and thereby resulted in failure to prevent development of cardiac hypertrophy, whereas other effects of enalapril, such as inhibition of kininase II and thereby potentiation of the vasodilator action of bradykinin,41 may have contributed to similar hemodynamic results as those caused by losartan. However, since the same or even lower dose of enalapril prevents the development7 or causes the prompt regression21 of pressure overload-induced cardiac hypertrophy in animal models with high PRA, this possibility seems to be unlikely.
Conclusions
Volume overload induced by opening an aortocaval shunt increases LVEDP and causes RV hypertrophy and LV eccentric hypertrophy within 7 days after sur- 
